Placental Stem Cell Therapy Market Size, Trends, Growth | Forecast Report 2022-2030

According to Latest Study, the global placental stem cell therapy market was valued at US$ 0.9 billion in 2021 and is expected to reach US$ 4.7 billion by 2030 with a CAGR of 22% from 2022 to 2030.

According to Latest Study, the global placental stem cell therapy market was valued at US$ 0.9 billion in 2021 and is expected to reach US$ 4.7 billion by 2030 with a CAGR of 22% from 2022 to 2030.

Mesenchymal stem cells are emerging as powerful immunomodulators that are playing a key role in advancements made for the treatment of severe COVID-19 patients. MSC-based therapies hold future prospects for companies in the placental stem cell therapy market to create therapeutics for bronchopulmonary dysplasia (BPD) in infants born prematurely. MSCs have proven paracrine activity, which helps migrate toward inflamed sites and improves outcomes in patients suffering from neurological disorders. Ethical issues and immune mediated rejection of transplanted cells are posing as hurdles in the treatment of congenital metabolic diseases. Hence, companies should increase the production of human amniotic epithelial cells (hAECs) that are emerging as an alternative to hepatocyte transplantation (HT) for patients suffering from congenital metabolic diseases.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37827

Key Findings

Robust Analytics and Independent Measurement Systems to Enrich Market Landscape: Players are keenly adopting technologies and techniques to ensure consistent quality of stem cells in order to expand the clinical applications of placental stem cell therapies. Extensive research on the characterization of placental stem cell therapies pivots on strides in biobanking technologies.

Rising Number of Allogeneic Stem Cell Transplantations Holds Promise for Regenerative Medicine: Growing utility of human amniotic/amnion epithelial cells (hAECs) in regenerative medicine has catalyzed significant investments in the placental stem cell therapy market over the past few years. Allogeneic hAECs are showing potential for leukemia and bronchopulmonary dysplasia (BPD) in various phases of clinical trials. The growing number of allogeneic stem cell transplantation procedures in developed nations has enriched the sales prospects in the placental stem cell therapy market.

MSC-based Cell Therapies Expand Prospects: Continued advances in cell-based therapies have engendered industry efforts in utilizing placental stem cell therapy for various diseases, expanding the sales prospects of the placental stem cell therapy market. These mainly include lung and liver injury, neurological disorders, acute kidney failure, and cardiovascular diseases. Especially in case of neurological disorders, mesenchymal stem/stromal cells (MSCs)-based cell therapy products are showing good therapeutic efficacy. For instance, allogeneic stem cell transplants have shown effectiveness in Alzheimer’s disease in animal studies.

  • In terms of application, the global placental stem cell therapy market has been divided into hematologic malignancies and disorders, congenital immunodeficiency disorders, metabolic disorders, neurological disorders, and others.
  • The neurological disorders segment held a significant share of the global placental stem cell therapy market in 2021. Based on end user, the global placental stem cell therapy market has been split into hospitals & specialty clinics, clinical research organizations, and research institutes & academies.
  • The clinical research organizations segment held a significant share of the global placental stem cell therapy market in 2021.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37827

Ease of Procurement

  • Placenta is a vascular organ with a known duration of life, and is only developed during the occurrence of pregnancy. It attaches to the uterine wall and the umbilical cord, which connects between the mother and the fetus, thereby supporting the growth and development of the fetus.
  • Placenta plays an important role in transfer of gases, nutrients, and removal of waste products during pregnancy, which is vital for the sustenance of the fetus
  • Placenta stem cells also provide additional benefit as compared to that offered by other tissues. These cells are easy to procure, with no harm to the mother or the baby. There are also no ethical issues associated with obtaining placenta, as it is considered a biological waste after birth.
  • Placenta has high cell yield and is less exposed to infection, as it comes from an infection-naïve environment. This makes rendering any disease transmission less likely. This factor is considered a major driver of the placental stem cell therapy market.
  • Rise in the number of storage banks and the awareness among people are key factors boosting the adoption of placental stem cell therapy

Prominent Regions

Asia Pacific held a major share of the global placental stem cell therapy market in 2019. Presence of key players and growth strategies adopted by these players are key factors driving the placental stem cell therapy market in the region. North America accounted for the second-largest share of the global placental stem cell therapy market in 2019. The expansion of the market in the region can be attributed to a well-developed healthcare sector. The placental stem cell therapy market in North America is likely to expand at a rapid pace during the forecast period. Technological developments in placental stem cell therapy is another major factor that is likely to propel the placental stem cell therapy market in the region.

Prominent players operating in the global placental stem cell therapy market include Lifebank Stem Cell Banking Celularity, Inc. Americord Registry ReeLabsPvt. Ltd. Pluristem Therapeutics, Inc. Mesoblast Limited ReNeuron Group plc Athersys, Inc.

Market Segmentation

By Application

  • Hematologic Malignancies and Disorders
  • Congenital Immunodeficiency Disorders
  • Metabolic Disorders
  • Neurological Disorders
  • Others

By End User

  • Hospitals & Specialty Clinics
  • Clinical Research Organizations
  • Research Institutes & Academies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37827

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333